Vir Biotechnology price target lowered to $85 from $95 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vir Biotechnology to $85 from $95 and keeps a Buy rating on the shares. The analyst believes the company’s registrational pathway in chronic hepatitis delta virus may take longer than previously anticipated with a potential curative regimen launching in 2028. However, Vir’s viral hepatitis programs including are among the leaders in the space, the analyst tells investors in a research note.